Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions
© 2023 the author(s), published by De Gruyter, Berlin/Boston..
Background: Statins are one of the most prescribed medications in developed countries as the treatment of choice for reducing cholesterol and preventing cardiovascular diseases. However, a large proportion of patients experience adverse drug reactions, especially myotoxicity. Among the factors that influence the diversity of response, pharmacogenetics emerges as a relevant factor of influence in inter-individual differences in response to statins and can be useful in the prevention of adverse drug effects.
Content: A systematic review was performed of current knowledge of the influence of pharmacogenetics on the occurrence and prevention of statin-associated adverse reactions and clinical benefits of preemptive pharmacogenetics testing.
Summary: Genetic variants SLCO1B1 (rs4149056) for all statins; ABCG2 (rs2231142) for rosuvastatin; or CYP2C9 (rs1799853 and rs1057910) for fluvastatin are associated with an increase in muscle-related adverse effects and poor treatment adherence. Besides, various inhibitors of these transporters and biotransformation enzymes increase the systemic exposure of statins, thereby favoring the occurrence of adverse drug reactions.
Outlook: The clinical preemptive testing of this pharmacogenetic panel would largely prevent the incidence of adverse drug reactions. Standardized methods should be used for the identification of adverse effects and the performance and interpretation of genotyping test results. Standardization would allow to obtain more conclusive results about the association between SLCO1B1, ABCG and CYP2C9 variants and the occurrence of adverse drug reactions. As a result, more personalized recommendations could be established for each statin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Advances in laboratory medicine - 4(2023), 4 vom: 03. Dez., Seite 341-352 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sainz de Medrano Sainz, Jaime I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse reactions |
|---|
| Anmerkungen: |
Date Revised 19.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1515/almed-2023-0123 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365971960 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365971960 | ||
| 003 | DE-627 | ||
| 005 | 20231227134532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/almed-2023-0123 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1232.xml |
| 035 | |a (DE-627)NLM365971960 | ||
| 035 | |a (NLM)38106499 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sainz de Medrano Sainz, Jaime I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 the author(s), published by De Gruyter, Berlin/Boston. | ||
| 520 | |a Background: Statins are one of the most prescribed medications in developed countries as the treatment of choice for reducing cholesterol and preventing cardiovascular diseases. However, a large proportion of patients experience adverse drug reactions, especially myotoxicity. Among the factors that influence the diversity of response, pharmacogenetics emerges as a relevant factor of influence in inter-individual differences in response to statins and can be useful in the prevention of adverse drug effects | ||
| 520 | |a Content: A systematic review was performed of current knowledge of the influence of pharmacogenetics on the occurrence and prevention of statin-associated adverse reactions and clinical benefits of preemptive pharmacogenetics testing | ||
| 520 | |a Summary: Genetic variants SLCO1B1 (rs4149056) for all statins; ABCG2 (rs2231142) for rosuvastatin; or CYP2C9 (rs1799853 and rs1057910) for fluvastatin are associated with an increase in muscle-related adverse effects and poor treatment adherence. Besides, various inhibitors of these transporters and biotransformation enzymes increase the systemic exposure of statins, thereby favoring the occurrence of adverse drug reactions | ||
| 520 | |a Outlook: The clinical preemptive testing of this pharmacogenetic panel would largely prevent the incidence of adverse drug reactions. Standardized methods should be used for the identification of adverse effects and the performance and interpretation of genotyping test results. Standardization would allow to obtain more conclusive results about the association between SLCO1B1, ABCG and CYP2C9 variants and the occurrence of adverse drug reactions. As a result, more personalized recommendations could be established for each statin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SLCO1B1 | |
| 650 | 4 | |a adverse reactions | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a statins | |
| 700 | 1 | |a Brunet Serra, Mercè |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in laboratory medicine |d 2020 |g 4(2023), 4 vom: 03. Dez., Seite 341-352 |w (DE-627)NLM358605490 |x 2628-491X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:4 |g day:03 |g month:12 |g pages:341-352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/almed-2023-0123 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 4 |b 03 |c 12 |h 341-352 | ||